Cytogenomic SNP Microarray, Fetal

Cytonomic SNP microarray testing is used to identify genomic imbalances (deletions and duplications) and may be used to further characterize abnormalities identified by chromosome analysis, including unbalanced translocations, recombinant chromosomes, markers, and ring chromosomes. Regions of homozygosity (ROH) can also be identified. It is the recommended first-tier test for patients undergoing prenatal diagnosis for the indication of a fetal structural abnormality detected by ultrasound (unless the structural abnormality is strongly suggestive of a specific aneuploidy, in which case, karyotype with or without FISH may be offered before genomic microarray).

Disease Overview

Diagnostic Issues

- Many abnormal phenotypes are associated with chromosomal imbalances
- Chromosome analysis has limited ability to detect copy number abnormalities less than 10-20 Mb in size
- Genomic microarray can detect chromosomal imbalances at a much higher level of resolution than standard chromosome analysis
- Genomic microarray can detect ROH, which may indicate an increased risk for autosomal recessive (AR) disease for genes contained within the ROH, and/or the risk of an imprinting disorder due to uniparental disomy (UPD), or molar pregnancy
- Identification of specific abnormalities may be helpful in medical management and planning for special needs

Test Interpretation

Diagnostic Yield

- 100% for nonmosaic aneuploidy detectable by karyotype
- Among cases with a normal karyotype, microarray studies reveal clinically relevant copy number variants (CNVs) in:
  - ~6% of fetuses with a structural anomaly, may be higher depending on anomaly
  - ~2% whose indication is advanced maternal age or positive aneuploidy screen
- The diagnostic yield varies by patient population and the presence of comorbidities

Results

- A written summary and an interpretation of the microarray findings are provided
- CNV evaluation is performed in accordance with recommendations by the American College of Medical Genetics and Genomics (ACMG):
  - Standard 5-tier classification terminology is used:
    - Pathogenic
    - Likely pathogenic

Tests to Consider

Cytogenomic SNP Microarray - Fetal 2002366
Method: Genomic Microarray (Oligo-SNP Array)
- Identifies genomic abnormalities (e.g., aneuploidy, deletions, duplications)
- Performed on direct and cultured amniotic fluid and chorionic villus sampling (CVS) specimens

Chromosome FISH, Amniotic Fluid with Reflex to Chromosome Analysis or Genomic Microarray 2011130
Method: Fluorescence in situ Hybridization (FISH)
- Rapid detection of aneuploidy involving chromosomes 13, 18, 21, X, and Y
- If results of aneuploidy FISH panel are normal, genomic microarray analysis will be performed
- If results of aneuploidy FISH panel are abnormal, chromosome analysis will be performed
- Performed on uncultured amniotic fluid

Chromosome FISH, Chorionic Villus with Reflex to Chromosome Analysis or Genomic Microarray 2011131
Method: Fluorescence in situ Hybridization (FISH)
- Rapid detection of aneuploidy involving chromosomes 13, 18, 21, X, and Y
- If results of aneuploidy FISH panel are normal, genomic microarray analysis will be performed
- If results of aneuploidy FISH panel are abnormal, chromosome analysis will be performed
- Performed on uncultured CVS

Chromosome Analysis, Amniotic Fluid, with Reflex to Genomic Microarray 2008367
Method: Giemsa Band/Genomic Microarray (Oligo-SNP Array)
- Chromosome analysis is used for detection of aneuploidy and other chromosomal abnormalities (e.g., large deletions/duplications, translocations, inversions, marker chromosomes)
If results of chromosome analysis are normal, genomic microarray analysis will be performed.

**Related Tests**

Other fetal testing for cytogenetic abnormalities

- Chromosome FISH, Prenatal 2002297
  - Method: Fluorescence in situ Hybridization (FISH)
  - Rapid detection of aneuploidy involving chromosomes 13, 18, 21, X, and Y
  - Performed on uncultured amniotic fluid

- Chromosome Analysis, Amniotic Fluid 2002293
  - Method: Giemsa Band
  - Detection of aneuploidy and other chromosomal abnormalities (large deletions/duplications, translocations, inversions, marker chromosomes)
  - Performed on cultured amniotic fluid

- Chromosome Analysis, Chorionic Villus 2002291
  - Method: Giemsa Band
  - Detection of aneuploidy and other chromosomal abnormalities (large deletions/duplications, translocations, inversions, marker chromosomes)
  - Performed on cultured CVS

---

**Result** | **Description**
---|---
Normal | No clinically significant CNV or ROH detected
Abnormal | One or more clinically significant CNV, ROH, aneuploidy, or triploidy detected
Uncertain | One or more CNVs of uncertain clinical significance detected
  - Insufficient evidence for unequivocal determination of clinical significance available at the time of review
  - AR risk
  - Uncertain ROH: Risk for AR disease and/or imprinting disorder due to UPD
  - Testing may suggest relatedness between the parents of the tested individual

---

**Reporting Criteria**

- Deletions >1 Mb and duplications >2 Mb are generally reported, dependent on genomic content
- CNVs classified as VUS are generally reported when found to have suspected clinical relevance based on information available at the time of review, or when meeting size criteria
- Total autosomal homozygosity >5% is generally reported
  - Only autosomal ROH >3 Mb are considered for this estimate
- Single terminal ROH >3 Mb or single interstitial ROH >10-20 Mb are generally reported, dependent upon chromosomal location and likelihood of imprinting disorder
- Recessive disease risk and recurrent CNVs with established reduced penetrance are generally reported
- Known or expected pathogenic CNVs affecting genes with known clinical significance but which are unrelated to the indication for testing will generally be reported
- CNVs classified as likely benign or benign that are devoid of relevant gene content or reported as common findings in the general population are generally not reported

---

**Limitations**

- Does not detect:
  - CNVs below the limit of resolution of the testing platform
  - Sequence-level variants (mutations), including point mutations and small insertions/deletions
  - Balanced chromosomal rearrangements (translocations, inversions, and insertions)
  - Imbalances of the mitochondrial genome
  - Low-level mosaicism (generally <20-30%)
  - Most cases of tetraploidy
Related Information

Prenatal Screening and Diagnosis for Chromosomal Abnormalities and Neural Tube Defects
Prenatal Screening and Diagnosis for Chromosomal Abnormalities and Neural Tube Defects Algorithm

ARUP Laboratories is a nonprofit enterprise of the University of Utah and its Department of Pathology, 500 Chipeta Way, Salt Lake City, UT 84108
(800) 522-2787 | (801) 583-2787 | aruplab.com | arupconsult.com
Content Review April 2020 | Last Update January 2021